Maria Chiara Tisi,Michele Wieczorek,Marcello Riva
Maria Chiara Tisi
Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), setting as the new standard of care. Below, we describe the case history of a 69-year-old fema...
[CAR-T cell therapy in an elderly patient with DLBCL and early relapse ( [0.03%]
老年DLBCL早期复发患者进行CAR-T细胞治疗
Enrico Orciuolo
Enrico Orciuolo
We report a successful therapeutic case of axi-cell therapy in an elderly patient diagnosed with diffuse large B-cell lymphoma (DLBCL), experiencing early relapse after first-line treatment. The complications that arose during hospitalizati...
[Refractory DLBCL to a polatuzumab-containing regimen: efficacy of CAR-T therapy in second line with radiotherapy bridging] [0.03%]
[对ポラツズマブ含む化学療法抵抗性DLBCL患者のCAR-T治療第2線導入時の効果と化学放射線橋接療法の有用性]
Guido Gini,Francesco Saraceni
Guido Gini
DLBCL represents the prototype of aggressive lymphomas; despite therapeutic advances, a substantial proportion of patients remain refractory to first-line treatment. Anti-CD19 CAR-T therapy has revolutionized the second-line setting for pat...
[Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL] [0.03%]
[超越合并症：CAR-T作为二线DLBCL虚弱患者的高效安全选择]
Eugenio Galli
Eugenio Galli
CD19 CAR-T therapy is the second-line standard for relapsed/refractory DLBCL, yet the management of frail patients remains debated due to toxicity and non-relapse mortality risks. We report a 74-year-old man with high-risk DLBCL and multipl...
[CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy] [0.03%]
初程化疗免疫治疗后早期复发的CAR-T细胞免疫治疗
Livia Donzelli,Alice Di Rocco
Livia Donzelli
CAR-T therapies represent a major advance in the management of large B-cell lymphomas. Axi-cel, the only product approved in Italy as a second-line treatment, demonstrated superiority over standard therapy in the randomized phase 3 ZUMA-7 t...
[Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome] [0.03%]
[Axi-cel治疗一线治疗无效的高大B细胞淋巴瘤患者的疗效：早期识别和转诊潜在CAR-T候选患者对预后的影响]
Beatrice Casadei,Pier Luigi Zinzani
Beatrice Casadei
CAR-T cell therapy has revolutionized second-line treatment for patients with refractory/relapsed large B-cell lymphoma within 12 months, demonstrating clear superiority in terms of both response rate and survival compared to salvage chemot...